Research Study

Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)
Principal Investigator 
Graham Wong

Overview

Body Locations and Systems 
Heart Disease
ClinicalTrials.gov# 
NCT01492361
Status 
Closed to Recruitment
Study Start/End 
Aug 20, 2012 to Dec 31, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jaclyn Chow, Research Coordinator
Phone 
604-875-5324
Email Address 
jackie.chow@vch.ca
Purpose of Study 

AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) being developed by Amarin Pharma Inc. for the treatment of hypertriglyceridemia. The purpose of this study is to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.